S. Gilbert

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Sarah C. Gilbert, Sarah C Gilbert, Sarah c. Gilbert, S. Gilbert, Sarah Catherine Gilbert, S. C. Gilbert, S C Gilbert, Sarah Gilbert, S Gilbert
Publication record
337 papers · 32,399 citations · H-index 88

PAPERS

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
202312 citationsauthor #19
Vaccine supply chains: priority areas of action emerging from the COVID-19 pandemic
20236 citationsauthor #4
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
202321 citationsauthor #21
Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs
202319 citationsauthor #15
Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model
202323 citationsauthor #12
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley Fever in adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
202313 citationsauthor #15
Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial
20220 citationsauthor #34
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
202213 citationsauthor #46
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
202210 citationsauthor #11
Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model
202214 citationsauthor #14
Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamsters
20224 citationsauthor #15
Expanding the Malaria Antibody Toolkit: Development and Characterisation of Plasmodium falciparum RH5, CyRPA, and CSP Recombinant Human Monoclonal Antibodies
20227 citationsauthor #15
Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility
20228 citationsauthor #31
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
202227 citationsauthor #15
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
202220 citationsauthor #34
Lessons from the pandemic: Responding to emerging zoonotic viral diseases—a Keystone Symposia report
20225 citationsauthor #26
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa
20224 citationsauthor #14
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
202237 citationsauthor #52
Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions
20226 citationsauthor #13
SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription
202143 citationsauthor #7
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models
2021225 citationsauthor #19
Transcriptomic Profiling of Dromedary Camels Immunised with a MERS Vaccine Candidate
20211 citationsauthor #5
Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
202110 citationsauthor #36
Heterologous vaccination regimens with self-amplifying RNA and Adenoviral 1 COVID vaccines induce superior immune responses than single dose vaccine 2 regimens in mice 3
20210 citationsauthor #13
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
2021467 citationsauthor #61
ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge
20210 citationsauthor #14
ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV
20218 citationsauthor #33
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
202188 citationsauthor #22
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
202128 citationsauthor #25
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
2021210 citationsauthor #34
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
202132 citationsauthor #42
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
202174 citationsauthor #22
Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies.
20210 citationsauthor #9
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
20211,038 citationsauthor #79
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
20211,094 citationsauthor #9
ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys
202115 citationsauthor #12
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
2021162 citationsauthor #54
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
202113 citationsauthor #44
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
2021107 citationsauthor #35
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques
202146 citationsauthor #19
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
20217 citationsauthor #44
Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses
20214 citationsauthor #53
Heterologous vaccination regimens with self-amplifying RNA and Adenoviral 1 COVID vaccines induce superior immune responses than single dose vaccine 2 regimens in mice 3
20210 citationsauthor #13
Recombinant protein vaccines against SARS-CoV-2
20215 citationsauthor #1
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)
202128 citationsauthor #34
Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity
20217 citationsauthor #43
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
20218 citationsauthor #44
Manufacturing a chimpanzee adenovirus‐vectored SARS‐CoV‐2 vaccine to meet global needs
202149 citationsauthor #33
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
202173 citationsauthor #61
Heterologous vaccination regimens with self-amplifying RNA and Adenoviral 1 COVID vaccines induce superior immune responses than single dose vaccine 2 regimens in mice 3
20210 citationsauthor #13
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
2021735 citationsauthor #39
Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa
202198 citationsauthor #46
SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription
20210 citationsauthor #7
Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice
202118 citationsauthor #7
Why acute inflammatory response can happen after Adenoviral Vector Vaccines; Is the interleukin 6 the secret and how circumvent that, Is by adding polyethylene glycol (PEG)?
20210 citationsauthor #8
ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge
202138 citationsauthor #14
Heterologous vaccination regimens with self-amplifying RNA and Adenoviral 1 COVID vaccines induce superior immune responses than single dose vaccine 2 regimens in mice 3
20214 citationsauthor #13
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
202170 citationsauthor #18
Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
20210 citationsauthor #36
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial
202142 citationsauthor #22
Heterologous vaccination regimens with self-amplifying RNA and Adenoviral 1 COVID vaccines induce robust immune responses in mice 2
20210 citationsauthor #15
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
2021113 citationsauthor #14
CD4+ T Follicular Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4+ Cells
202093 citationsauthor #8
Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule
202012 citationsauthor #7
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
202015 citationsauthor #36
A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques
202093 citationsauthor #13
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
2020123 citationsauthor #40
Immunological and pathological outcomes of SARS-CoV-2 challenge after formalin-inactivated vaccine immunisation of ferrets and rhesus macaques
20206 citationsauthor #34
(2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111.
202035 citationsauthor #63
A single dose of ChAdOx1 MERS provides broad protective immunity against a variety of MERS-CoV strains
202016 citationsauthor #13
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
2020490 citationsauthor #44
A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice
202077 citationsauthor #17
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
20201,784 citationsauthor #31
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
2020822 citationsauthor #36
ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
2020256 citationsauthor #34
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
20201,322 citationsauthor #62
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
20204,018 citationsauthor #81
Vaccine platforms for the prevention of Lassa fever
201949 citationsauthor #3
Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice
201933 citationsauthor #7
Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge
201947 citationsauthor #9
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
201927 citationsauthor #17
Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels
201977 citationsauthor #24
Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
201936 citationsauthor #6
Edinburgh Research Explorer UK vaccines network
20190 citationsauthor #3
UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments
201923 citationsauthor #5
A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters
201960 citationsauthor #14
Repertoire sharing between CD4(+) T follicular helper cells in peripheral blood and tonsil
20190 citationsauthor #7
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
201926 citationsauthor #16
Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers
201923 citationsauthor #36
A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol
201914 citationsauthor #5
Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components
201932 citationsauthor #12
Development of low bio-containment assays to characterise the antibody responses in pigs to Nipah virus vaccine candidates
20192 citationsauthor #5
CD4+ T follicular helper (Tfh) cells in human tonsil and blood are clonally convergent, but divergent from non-Tfh CD4+ cells
20191 citationsauthor #7
Modified Vaccinia Ankara–Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Nasopharynx-Associated Lymphoid Tissue
201922 citationsauthor #8
CLINICAL DEVELOPMENT OF VIRAL VECTORED VACCINES AGAINST MERS-COV
20180 citationsauthor #9
Novel MVA-based vaccine expressing influenza NP and M1 activates cross-reactive T cell responses in human nasopharynx-associated lymphoid tissue (NALT)
20180 citationsauthor #10
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors
201882 citationsauthor #17
Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults
2018121 citationsauthor #19
A naturally protective epitope of limited variability as an influenza vaccine target
201835 citationsauthor #15
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
201845 citationsauthor #34

TIMELINE

1994 72 citations

1995 579 citations

1996 102 citations

1997 243 citations

1998 1,576 citations

1999 462 citations

2000 88 citations

2001 358 citations

2002 364 citations

2003 912 citations

2004 1,167 citations

2005 1,230 citations

2006 1,335 citations

2007 442 citations

2008 713 citations

2009 770 citations

2010 631 citations

2011 1,063 citations

2012 1,742 citations

2013 1,345 citations

2014 518 citations

2015 685 citations

2016 314 citations

2017 456 citations

2018 404 citations

2019 472 citations

2020 9,162 citations

2021 4,960 citations

2022 155 citations

2023 94 citations

S. Gilbert

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT